5K48
VIM-2 Metallo Beta Lactamase in complex with 3-(mercaptomethyl)-[1,1'-biphenyl]-4-carboxylic acid
5K48 の概要
| エントリーDOI | 10.2210/pdb5k48/pdb |
| 分子名称 | Beta-lactamase VIM-2, 4-phenyl-2-(sulfanylmethyl)benzoic acid, FORMIC ACID, ... (5 entities in total) |
| 機能のキーワード | metallo beta-lactamase, antibiotic resistance, carbapenamase. inhibitor, hydrolase |
| 由来する生物種 | Pseudomonas aeruginosa |
| タンパク質・核酸の鎖数 | 2 |
| 化学式量合計 | 52498.17 |
| 構造登録者 | Zollman, D.,McDonough, M.,Brem, J.,Schofield, C. (登録日: 2016-05-20, 公開日: 2017-06-07, 最終更新日: 2024-01-10) |
| 主引用文献 | Cain, R.,Brem, J.,Zollman, D.,McDonough, M.A.,Johnson, R.M.,Spencer, J.,Makena, A.,Abboud, M.I.,Cahill, S.,Lee, S.Y.,McHugh, P.J.,Schofield, C.J.,Fishwick, C.W.G. In Silico Fragment-Based Design Identifies Subfamily B1 Metallo-beta-lactamase Inhibitors. J. Med. Chem., 61:1255-1260, 2018 Cited by PubMed Abstract: Zinc ion-dependent β-lactamases (MBLs) catalyze the hydrolysis of almost all β-lactam antibiotics and resist the action of clinically available β-lactamase inhibitors. We report how application of in silico fragment-based molecular design employing thiol-mediated metal anchorage leads to potent MBL inhibitors. The new inhibitors manifest potent inhibition of clinically important B1 subfamily MBLs, including the widespread NDM-1, IMP-1, and VIM-2 enzymes; with lower potency, some of them also inhibit clinically relevant Class A and D serine-β-lactamases. The inhibitors show selectivity for bacterial MBL enzymes compared to that for human MBL fold nucleases. Cocrystallization of one inhibitor, which shows potentiation of Meropenem activity against MBL-expressing Enterobacteriaceae, with VIM-2 reveals an unexpected binding mode, involving interactions with residues from conserved active site bordering loops. PubMed: 29271657DOI: 10.1021/acs.jmedchem.7b01728 主引用文献が同じPDBエントリー |
| 実験手法 | X-RAY DIFFRACTION (1.744 Å) |
構造検証レポート
検証レポート(詳細版)
をダウンロード






